Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CYT | Common Stock | Award | $7.45K | +5K | +121.95% | $1.49 | 9.1K | Jan 13, 2023 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CYT | Stock Option (Right to Buy) | Award | $0 | +114K | $0.00 | 114K | Feb 3, 2023 | Common Stock | 114K | $1.69 | Direct | F2 |
Id | Content |
---|---|
F1 | The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period. |
F2 | The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. |